Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002200 · ClinicalTrials.gov registry record · NA
A Study of 1592U89 in HIV-Infected Adults
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002200: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002200 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002200, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
Interventions
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002200 record still lists
NCT00002200 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Abacavir sulfate is the first listed.
NCT00002200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002200 about?
NCT00002200 is a clinical study titled "A Study of 1592U89 in HIV-Infected Adults". The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
What is the current status of trial NCT00002200?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002200?
The interventions under investigation include: Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002200?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.